Intermediate duration neuromuscular blocking agents and antagonists thereof
View Patent ↗The invention provides novel neuromuscular blocking agents, methods of using the neuromuscular blocking agents as well as reagents, methods and kits for reversing the effects of the neuromuscular blocking agents.
1. A neuromuscular blocking agent selected from the group consisting of:
and combinations thereof.
2. A composition comprising a pharmaceutically acceptable carrier and an amount of a neuromuscular blocking agent sufficient to paralyze a mammalian subject, wherein the neuromuscular blocking agent is selected from the group consisting of:
and a combination thereof.
3. The composition of claim 2 , wherein the neuromuscular blocking agent has the following structure:
4. A method of inducing a neuromuscular blockade in a mammal comprising administering to the mammal a composition comprising an amount of a neuromuscular blocking agent sufficient to paralyze the mammal, wherein the neuromuscular blocking agent is selected from the group consisting of:
and a combination thereof.
5. The method of claim 4 , wherein the neuromuscular blocking agent has the following structure:
6. The method of claim 4 , wherein the mammal is also subjected to general anesthesia.
7. The method of claim 4 , wherein the neuromuscular blocking agent is administered in an amount effective to paralyze the mammal.
8. The method of claim 4 , wherein the mammal is a human.
9. A method of reversing a neuromuscular blockade in a mammal comprising administering to the mammal an effective amount of cysteine, N-acetylcysteine, glutathione, homocysteine, methionine, S-adenosyl-methionine, penicillamine, a combination thereof or a pharmaceutically acceptable salt thereof,
wherein the neuromuscular blockade is generated by the method comprising inducing a neuromuscular blockade in a mammal by administering to the mammal a composition comprising an amount of a neuromuscular blocking agent sufficient to paralyze the mammal, wherein the neuromuscular blocking agent is selected from the group consisting of:
and a combination thereof.
10. The method of claim 9 , wherein cysteine is administered.
11. The method of claim 9 , wherein glutathione is administered.
12. The method of claim 9 , wherein a combination of cysteine and glutathione are administered.
13. The method of claim 9 , wherein the cysteine, N-acetylcysteine, glutathione, homocysteine, methionine, S-adenosyl-methionine, penicillamine, a combination thereof or a pharmaceutically acceptable salt thereof, are administered intravenously, in combination with a pharmaceutically acceptable liquid carrier.
14. The method of claim 9 , wherein the cysteine, N-acetylcysteine, glutathione, homocysteine, methionine, S-adenosyl-methionine, penicillamine, a combination thereof or a pharmaceutically acceptable salt thereof, are administered in a dosage of about 0.1 mg/kg to about 500 mg/kg.
15. The method of claim 9 , wherein the mammal is a domestic or zoo animal.
16. The method of claim 9 , wherein the mammal is a human.
17. A kit comprising, separately packaged,
(a) an effective amount of a neuromuscular blocking agent selected from the group consisting of:
and combinations thereof,
(b) an effective amount of an antagonist to the neuromuscular blocking agent, and
(c) instructions directing the user to employ the antagonist to reverse the effects of the blocking agent on a mammal to which the blocking agent is administered; wherein the antagonist is cysteine, N-acetylcysteine, glutathione, homocysteine, methionine, S-adenosyl-methionine, penicillamine, a combination thereof, or a pharmaceutically acceptable salt thereof.
18. The kit of claim 17 , wherein the neuromuscular blocking agent is formulated to be administered intravenously, in combination with a pharmaceutically acceptable liquid carrier.
19. The kit of claim 17 , wherein the antagonist is formulated to be administered intravenously, in combination with a pharmaceutically acceptable liquid carrier.
20. The kit of claim 17 , wherein the antagonist is cysteine, glutathione, a combination thereof or a pharmaceutically acceptable salt thereof.
21. The kit of claim 17 , wherein the antagonist is a combination of cysteine and glutathione.
22. The kit of claim 17 , wherein the neuromuscular blocking agent has the following structure: